Business Wire

NORTHLEAF-CAPITAL

22.6.2021 20:02:10 CEST | Business Wire | Press release

Share
Northleaf Appoints Shane Feeney to Lead and Expand Its Well-established Global Secondaries Business

Northleaf Capital Partners (Northleaf) today announced that Shane Feeney has joined the firm as Global Head of Secondaries, based in Toronto.

In this role, Feeney will oversee all aspects of Northleaf’s secondaries program, building on the firm’s highly successful 18-year track record in global secondary investing and enhancing existing team capabilities as the secondaries market continues to expand rapidly.

Feeney most recently served as Senior Managing Director & Global Head of Private Equity at CPP Investments, one of the world’s largest institutional investors with $497.2 billion in assets under management as of March 31, 2021. In this role, Feeney led the teams responsible for CPP Investments’ direct private equity, Asia private equity, private equity funds and secondaries investments. Under Feeney’s leadership, CPP Investments’ private equity program assets under management grew by approximately $73.6 billion. In fiscal 2021, CPP Investments’ private equity program generated a net return of 36.3%.

“We’re excited that Shane is joining our team. He will have a significant and immediate impact on the continued growth and evolution of our secondaries business, as well as on our global private markets investment platform more broadly,” said Northleaf Managing Partner and Co-Founder Stuart Waugh. “We are delighted to attract a seasoned leader with proven principal investment experience and success in building global private equity teams and investment programs. We know Shane well – and he’s an ideal fit with our strategy, team and culture.”

To date, Northleaf has invested more than $3 billion across the full spectrum of secondary market transactions, leveraging the firm’s global private markets platform and long-standing private equity sponsor relationships for proprietary deal flow, due diligence information and insights.

Feeney said: “Northleaf is a world-class global private markets investment manager with extensive secondaries experience and a strong growth trajectory, particularly in light of its recent strategic partnership with Power Corporation affiliates Mackenzie Financial and Great-West Lifeco. I’m looking forward to working with everyone at Northleaf to build on the firm’s longstanding track record of developing innovative private equity and secondaries solutions for investors around the world.”

Feeney will report to Northleaf Managing Director and Co-Founder Michael Flood, who leads the firm’s global private equity program.

“Shane’s appointment is an important leadership addition for our firm and supplements the existing capabilities and skills of our integrated private equity team,” Flood said. “As GP-led continuation vehicles, single company secondaries and other structured transactions have become a greater part of the broader secondaries market, Shane’s principal investment expertise and leadership will complement our existing direct private equity strategy and team. We recognized early on that GP-led secondary transactions, especially single asset acquisitions, require differentiated investment skills in order to be successful as the secondary market continues to evolve.”

Feeney joined CPP Investments in 2010 from Bridgepoint Capital Ltd. in London. Prior to Bridgepoint, he was a partner and founding member of Hermes Private Equity’s direct investing business, until its transition to Bridgepoint in 2009. Previously, he was an Associate Director at Morgan Grenfell Private Equity in London and has served as a director of Livingston International, 99 Cents Only Stores, The Gates Corporation and Air Distribution Technologies. He holds a BA in economics from Dartmouth College and an MBA from INSEAD.

Northleaf is a leading global private equity investor with more than 20 years of experience and manages more than $9 billion of private equity commitments in pooled funds and separately managed accounts across three investment strategies: secondaries, directs and solutions. Northleaf’s secondaries program was launched in 2003 and has invested more than $3 billion across the full spectrum of private market secondary transaction types. The firm’s direct private equity strategy is led by Matt Shafer, Global Head of Direct Private Equity, based in New York, and has invested $1 billion in non-control direct investments alongside leading private equity sponsors, structured capital solutions for private equity-backed companies and single company secondary investments. Northleaf’s solutions program has raised more than $4 billion since inception in 2001 and specializes in building flexible investment programs that provide investors with access to the full spectrum of private equity strategies, sectors and geographies.

About Northleaf Capital Partners

Northleaf Capital Partners is a global private markets investment firm with US$16 billion in private equity, private credit and infrastructure commitments under management on behalf of public, corporate and multi-employer pension plans, endowments, foundations, financial institutions and family offices. Northleaf’s 150-person team, located in Toronto, Montreal, London, New York, Chicago, Menlo Park and Melbourne, is focused exclusively on sourcing, evaluating and managing private markets investments globally. Northleaf’s portfolio includes more than 400 active investments in 40 countries, with a focus on mid-market companies and assets. For more information on Northleaf, please visit www.northleafcapital.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Croma Pharma Launches AI-Driven Tech Venture to Revolutionize Aesthetic Medicine via Clinicore Platform23.4.2026 13:13:00 CEST | Press release

New structure to drive AI-powered innovation and international expansion Croma Pharma has launched a strategic joint venture to accelerate the development of Clinicore, its premium digital solution for aesthetic practices. This dedicated entity will focus on scaling the next generation of the platform while ensuring full continuity for existing users. Clinicore: Elevating Practice Excellence through AI Clinicore is a specialized SaaS (Software as a Service) solution designed to optimize the daily operations of aesthetic clinics. By automating patient management, scheduling, and administrative workflows, it enables healthcare professionals to focus entirely on patient care. A core element of the new strategy is a strong focus on Artificial Intelligence. Clinicore is evolving into a smart assistant, utilizing AI-driven features for automated treatment documentation, intelligent onboarding tools, and advanced process automation. This ensures that clinics can operate at maximum efficiency

NIQ Launches Commerce Lab to Build the Data and Measurement Layer for AI-Driven Commerce23.4.2026 13:00:00 CEST | Press release

NielsenIQ (NYSE: NIQ) today announced the launch of NIQ Commerce Lab, where the company is building the technology infrastructure for AI-driven commerce. The Lab will develop the data platforms, APIs, and measurement systems that power how products are discovered, evaluated, and purchased in AI-mediated environments. This includes what the industry often refers to as agentic commerce, but extends across quick commerce, social commerce, and other emerging channels—where AI is becoming the common layer shaping how consumers navigate choices and how decisions are made in real time. AI systems are rapidly moving from supporting decisions to making them—playing an increasingly central role in how commerce operates. Their effectiveness depends on the intelligence behind them. AI is Becoming the Operating Layer of Global Commerce NIQ ensures that the intelligence behind these systems is accurate, complete, and grounded in real-world behavior—reflecting how consumers actually buy, what product

Chiesi Reports Strong FY2025 Financial and Sustainability Results and Announces Leadership Transition Highlights23.4.2026 12:10:00 CEST | Press release

Strong FY2025 financial and sustainability results; leadership transition will support continuity and long-term growth Revenue up 8.2% to €3.6bn with double-digit growth in Rare Diseases and U.S. market Air sales at €1.886bn, growing 3.9% vs. 2024 - Care sales at €904m growing 13.3% vs. 2024 - Rare sales at €906m, growing 22.3% vs. 2024 Giuseppe Accogli leaving to pursue another opportunity, Group CFO Jean-Marc Bellemin named Interim CEO while new CEO search is underway Record €885m Research & Development (R&D) investment underscores continued commitment to innovation across respiratory, rare disease and specialty care Sustainability leadership further strengthened through B Corp recertification and progress on Carbon Minimal Inhaler (CMI) innovation Chiesi Group (“Chiesi”), an international research‑focused biopharmaceutical company and certified B Corp, today announced its financial results for the year ended 31 December 2025. Chiesi reported €3.625 billion in consolidated revenues,

REPLY S.p.A.: Shareholders’ Meeting Approves the 2025 Financial Statements23.4.2026 12:05:00 CEST | Press release

Consolidated turnover of €2,483.6 million (€2,300.5 million in 2024);Group net profits of €250.9 million (€211.1 million in 2024).Approval of the proposal to distribute a dividend of €1.35 per share.Approval of the plan for the purchase and/or disposal of treasury shares. The General Shareholders’ meeting of Reply S.p.A. [EXM, STAR: REY] held today approved the Financial Statements for the financial year 2025, confirming the distribution of a gross dividend of €1.35 per share. The dividend will be paid on 20 May 2026, with dividend date set on 18 May 2026 (record date on 19 May 2026). Approval of the 2025 financial statements The Reply Group closed the 2025 financial year with a consolidated turnover of €2,483.6 million, recording a 8.0% increase compared to €2,300.5 million in 2024. Consolidated EBITDA was €467.6 million, up 13.9% compared to €410.6 million recorded for the year 2024. EBIT, from January to December, was €397.1 million, up 18.5% compared to €330.4 million recorded for

Demand for GP Financing Is Rising, but the Managers Who Need It Most Are Finding It Hardest to Access23.4.2026 10:00:00 CEST | Press release

Corpay Private Markets publishes its fourth Lender Book Report, drawing on proprietary transaction data and live lender appetite tracking across 500+ lenders Corpay Private Markets, formerly Alpha Private Markets, today publishes the fourth edition of its Lender Book Report, focusing on GP financing across private markets. While demand for GP-level liquidity is rising – driven by longer fundraising cycles, slower exit activity, and increasing GP commitment requirements – access to financing is not expanding evenly. That is the central finding of the latest Lender Book Report. Unlike most research in the fund finance sector, which draws on surveys and reflects market sentiment, the Lender Book Report series is built on proprietary data. This edition combines insights from Alpha Match, Corpay Private Markets' lending intelligence platform tracking 500+ active lenders, with anonymised data from recent GP financing transactions. The data reveals a structural gap. Although the number of GP

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye